Press "Enter" to skip to content

The Finance Herald

Neurocrine’s $2.9 Billion Rare Obesity Bombshell Just Rewrote the Rules And Palatin Technologies (PTN) Is One of the Few Pure Plays Left

Neurocrine Biosciences’ lightning-fast $2.9 billion takeover of Soleno Therapeutics (NASDAQ: SLNO) isn’t your typical biotech M&A deal. It’s a full-blown repricing event that just lit a fire under an entirely…